Oncodesign ONCODESIGN: Oncodesign Confirms Its Very Good Results in 2021 and an Attractive Outlook For 2022
Group turnover up by 23% at €31.3 million Operating income and revenue of €36.2M, offsetting the foreseen discontinuation of the GSK subsidy (€8M) R&D investments amounting to €7.4M
Source: finanznachrichten.de